Nuvalent, Inc.
Subsidiary of GlaxoSmithKline (GSK)
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | ROS1Small molecule | Non-Small Cell Lung Cancer ROS1-Positive Non-Small Cell Lung Cancer | |
| Phase 3 | ALKSmall molecule | Non-Small Cell Lung Cancer ALK-Positive Non-Small Cell Lung Cancer | |
| Phase 1 | HER2Small molecule | Non-Small Cell Lung Cancer HER2-Mutant Non-Small Cell Lung Cancer |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(7)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $84M | $160M+ $1.1B short-term inv. | $109M-$92M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $84M | $116M+ $827M short-term inv. | $122M-$70M operating cash flow | report ↗ |
| 2025-Q2 | — | $81M | $127M+ $878M short-term inv. | $100M-$77M operating cash flow | report ↗ |
| 2025-Q1 | — | $74M | $121M+ $952M short-term inv. | $85M-$55M operating cash flow | report ↗ |
| 2024-Q3 | — | $61M | $369M+ $799M short-term inv. | $84M-$46M operating cash flow | report ↗ |
| 2024-Q2 | — | $49M | $78M+ $580M short-term inv. | $57M-$41M operating cash flow | report ↗ |
| 2024-Q1 | — | $39M | $99M+ $593M short-term inv. | $44M-$36M operating cash flow | report ↗ |
| 2023-Q3 | — | $30M | $88M+ $325M short-term inv. | $34M-$23M operating cash flow | report ↗ |
| 2023-Q2 | — | $26M | $71M+ $360M short-term inv. | $29M-$22M operating cash flow | report ↗ |
| 2023-Q1 | — | $22M | $90M+ $360M short-term inv. | $25M-$24M operating cash flow | report ↗ |
| 2022-Q3 | — | $15M | $76M+ $164M short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2022-Q2 | — | $14M | $76M+ $181M short-term inv. | $18M-$15M operating cash flow | report ↗ |
| 2022-Q1 | — | $13M | $67M+ $205M short-term inv. | $18M-$14M operating cash flow | report ↗ |
| 2021-Q3 | — | $9.1M | $246M+ $57M short-term inv. | $12M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $307M | $262M+ $1.1B short-term inv. | $425M-$275M operating cash flow | report ↗ |
Nuvalent, Inc. reported R&D spend of $306.97M, up 41.0% YoY, cash and equivalents of $261.75M, and a quarterly net burn of $425.38M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $218M | $146M+ $973M short-term inv. | $261M-$185M operating cash flow | report ↗ |
| 2023-FY | — | $113M | $335M+ $385M short-term inv. | $126M-$100M operating cash flow | report ↗ |
| 2022-FY | — | $64M | $242M+ $230M short-term inv. | $82M-$65M operating cash flow | report ↗ |
| 2021-FY | — | $36M | $69M+ $220M short-term inv. | $46M-$40M operating cash flow | report ↗ |